Outcomes of African-American kidney-transplant recipients treated with sirolimus, tacrolimus, and corticosteroids [1] (multiple letters)

Transplantation

Volumn 75, Issue 4, 2003, Pages 572-573

  Egidi, M Francesca ^a   Osama Gaber, A ^a   Hricik, Donald E ^b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; C PEPTIDE; CALCINEURIN INHIBITOR; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; STEROID; TACROLIMUS;

CAUCASIAN; DIABETES MELLITUS; DIABETIC DIET; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG INDICATION; DRUG WITHDRAWAL; ETHNIC DIFFERENCE; FOLLOW UP; GLUCOSE INTOLERANCE; GRAFT SURVIVAL; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INSULIN RESISTANCE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LETTER; NEGRO; NEPHROTOXICITY; OUTCOMES RESEARCH; PANCREAS DISEASE; PRIORITY JOURNAL; RISK FACTOR;

ADRENAL CORTEX HORMONES; AFRICAN CONTINENTAL ANCESTRY GROUP; DRUG THERAPY, COMBINATION; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; SIROLIMUS; TACROLIMUS;

EID: 0037468502     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000046940.27269.43     Document Type: Letter

References (0)